Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.

Abstract

BACKGROUND Hepatitis B virus (HBV) reactivation is a fatal complication in patients who receive chemotherapy or immunosuppressive therapy. We examined the effect of preventive entecavir (ETV), a new nucleoside analogue on HBV reactivation during chemotherapy or immunosuppressive therapy. METHODS Between February 2007 and September 2009, sixteen nucleoside analogue treatment-naive patients with chronic HBV infection (HB surface antigen [HBsAg] positive) who required chemotherapy or immunosuppressive therapy were enrolled. Referring to some guidelines, the patients received preventive ETV to reduce incidence of HBV reactivation, and were closely monitored for HBV markers. RESULTS HBV reactivation did not occur in any of the 16 patients and the indispensable treatments for their underlying diseases could be continued. However, HBV relapsed after preventive ETV was discontinued in 2 patients. CONCLUSIONS This study suggests that ETV is a useful option for preventing HBV reactivation in patients with chronic HBV infection.

DOI: 10.1016/j.ejim.2010.04.010
02040201520162017
Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Watanabe2010EntecavirIA, title={Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.}, author={Masaaki Watanabe and Akitaka Shibuya and Juichi Takada and Yoshiaki Tanaka and Yusuke Okuwaki and Tsutomu Minamino and Hisashi Hidaka and Takahide Nakazawa and Wasaburo Koizumi}, journal={European journal of internal medicine}, year={2010}, volume={21 4}, pages={333-7} }